Navigation Links
Living Cell Technologies' Diabetes Clinical Trial Authorized by New Zealand Government
Date:6/24/2009

SYDNEY and AUCKLAND, New Zealand, June 24 /PRNewswire/ -- Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) today announced that the New Zealand Minister of Health, the Honourable Tony Ryall, has authorized LCT's New Zealand Phase I/IIa clinical trial of DIABECELL(R) for insulin dependent diabetes.

The authorization confirms the conditions announced on 19 June 2009. One condition of the new authorization limits participation in the trial to patients with poorly controlled (brittle) diabetes. The remaining conditions are procedural rather than substantive in nature and LCT and the Middlemore Hospital clinical team conducting the trial, have requested the Regional Ethics Committee formally accept the changes required by the Minister.

LCT CEO Dr Paul Tan said: "We are pleased that the conditions have been finalized and LCT looks forward to commencing the trial within the next two months with the acceptance of the changes by the Ethics Committee."

Professor Bob Elliott, LCT Founder and Medical Director added: "The New Zealand diabetes trial is another major milestone for LCT. With two diabetes patients not requiring insulin following implants with encapsulated pig islet cells in our first study in Russia, we expect to see further benefit in more patients as we use higher doses of DIABECELL(R) in the New Zealand trial."

LCTs Phase I/IIa clinical trial in Russia started with a low dose of DIABECELL(R). In May 2009 LCT reported preliminary data showing sustained long term clinical benefit in patients treated with the DIABECELL(R) implant with no remarkable adverse events. Remarkably, two of seven patients given implants are now off insulin injections.

The New Zealand trial allows LCT to extend its Phase I/IIa clinical data with eight patients, four of whom are to receive double the initial dose used in Russia followed by four patients to receive triple the dose.

Dr John Baker, Clinical Director and Diabetes Physician at Middlemore Hospital, Auckland, who will be conducting the trial said, "There are many patients with poorly controlled diabetes who would qualify for this trial."

DIABECELL(R) is designed to normalize blood glucose levels in type 1 diabetes sufferers. DIABECELL(R) comprises encapsulated porcine insulin-producing cells which can be administered without the need to use immunosuppressive drugs.

Type 1 diabetes occurs when the body's own immune system destroys the insulin-producing cells of the pancreas (called beta cells). Five to 10 percent of the more than 200 million diabetics worldwide have insulin dependent type 1 diabetes. Type 1 diabetes is associated with kidney failure, blindness, nerve damage, life-threatening cardiovascular disease and limb amputations. Current treatment options include multiple daily injections of insulin.

For further information: www.lctglobal.com.

    CONTACT: Dr. Paul Tan
    Chief Executive Officer
    Mob: 021 608 784 (NZ)
    Tel: +64 9 276 2690
    ptan@lctglobal.com

    Mr John Cowan
    Finance & Administration Manager
    Tel: +64 9 276 2690
    jcowan@lctglobal.com

    Prof. Bob Elliott
    Medical Director
    Mob: +64 27 292 4177
    Tel:+64 9 276 2690
    relliott@lctglobal.com

    Paul Dekkers
    Investor and Media Relations
    Tel: +612 9237 2800
    pdekkers@bcg.com.au


'/>"/>
SOURCE Living Cell Technologies
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ADDAS Awareness Campaign Offers Resources and Education to Adults Living with AD/HD and Professionals Working With Them
2. Molecular probe paints cancer cells in living animals, Stanford researchers find
3. Scientists get first look at nanotubes inside living animals
4. Retirement Living TV Presents Sex, Drugs and Rock N Roll
5. CPF Living with IPF Patient Seminar to be Webcast Live October 13, 2007
6. Healthy Living Made Easy with New Diabetes Foodsmart e-Newsletter
7. National Energy Services Receives Repeat Orders From Golden Living and Cathedral Rock Skilled Nursing Facilities
8. Living Your Best Life: Adjusting Mind, Body and Spirit
9. How to Beat the High Cost of Living
10. Long Term Care Newsletter Debuts, Published by LTC Financial Partners; Advice on Living Better, Not Just Longer, With Financial Protection
11. A longer-living, healthier mouse that could hold clues to human aging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... January 23, 2017 , ... Steviva Ingredients, makers ... under the USDA National Organic Program (NOP) for its Portland SQF Level 2 ... organic production and handling systems to complement our current rigorous food-safety management systems,” ...
(Date:1/23/2017)... , ... January 23, 2017 , ... “The Inn at the Mill”: a story ... fears in her quest to become happy and content. , “The Inn at the ... has also lived in Germany and Vermont and is now living in Berks County on ...
(Date:1/23/2017)... ... 23, 2017 , ... Valentine’s Day is a time when many people celebrate romance and love ... may be looking for the ideal present, Atlanta-based Perimeter Plastic Surgery is offering ... free. Or, spend $200 and get $50 free. , “A lot of people just ...
(Date:1/21/2017)... ... 21, 2017 , ... Caronlab Australia, an Australian company known for health and ... Hilton Head, SC, where it benefited from outstanding meetings with major retail buyers. , ... wellness products. At this trade show, the company had the chance to demonstrate its ...
(Date:1/21/2017)... Barbara, CA (PRWEB) , ... January 21, 2017 ... ... its Director of Alumni Relations, Dianne Travis-Teague, the electrifying line-up of events for ... festivities for alumni, family, friends, and community. “Coming Home 2017” will be ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... , Jan. 23, 2017  Based on its ... & Sullivan recognizes Ansell, a global leader in ... Sullivan Company of the Year Award. Ansell,s comprehensive ... a wide global footprint have placed it in ... protection market. The Company,s established product line and ...
(Date:1/23/2017)... , Jan. 23, 2017 Research and ... Market - Forecast to 2021" report to their offering. ... The interventional radiology ... from USD 6.35 Billion in 2016, at a CAGR of 4.8%. ... The major factors driving the growth of this market ...
(Date:1/23/2017)... Jan. 23, 2017 MouthWatch LLC announced today that ... ranked as the best intraoral camera on DentalCompare,s list of ... spot overall. The #1 product was the CollaPlug Absorbable ... intraoral camera was "…incredibly popular because it is by far ... a small sticker price, it doesn,t sacrifice quality imaging." ...
Breaking Medicine Technology: